This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Abbosh PH , Rosenberg JE , Plimack ER
Circulating biomarkers to guide systemic therapy for urothelial carcinoma
Urol Oncol. 2016 Nov;34(11) :502-509
PMID: 27751785 URL: https://www.ncbi.nlm.nih.gov/pubmed/27751785
AbstractThere are very few biomarkers used to diagnose bladder cancer and no clinically approved biomarkers for prediction or prognostication of this disease. All currently available biomarkers are based on urine tests, and thus, they may not be applicable to patients with extravesical tumors. Biopsy of metastatic sites requires an invasive procedure, whereas serum-based markers, which can be easily obtained and serially measured, thus have obvious merit. These deficiencies may be overcome with advances in genome sequencing, identification of circulating tumor cells, and RNA-, protein-, and DNA-based biomarkers. Here, progress in circulating biomarkers in both superficial and invasive bladder cancer is described.
Notes1873-2496 Abbosh, Philip H Rosenberg, Jonathan E Plimack, Elizabeth R Review Journal article United States Urol Oncol. 2016 Nov;34(11):502-509. doi: 10.1016/j.urolonc.2016.08.019. Epub 2016 Oct 15.